Vanda Pharmaceuticals Inc. (FRA:VM4)
Germany · Delayed Price · Currency is EUR 4.540
0.00 (0.00%)
Last updated: Dec 1, 2025, 8:19 AM CET
Vanda Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 212.07 | 198.77 | 192.64 | 254.38 | 268.68 | 248.17 | Upgrade | |
Revenue Growth (YoY) | 11.12% | 3.18% | -24.27% | -5.32% | 8.27% | 9.23% | Upgrade |
Cost of Revenue | 11.8 | 11.31 | 14.8 | 24.28 | 25.63 | 23.36 | Upgrade |
Gross Profit | 200.27 | 187.46 | 177.84 | 230.1 | 243.05 | 224.8 | Upgrade |
Selling, General & Admin | 214.26 | 146.41 | 112.88 | 136.49 | 124.05 | 140.51 | Upgrade |
Research & Development | 100.11 | 74.43 | 76.82 | 85.77 | 75.36 | 55.58 | Upgrade |
Amortization of Goodwill & Intangibles | 7.01 | 7.27 | 2.09 | 1.52 | 1.48 | 1.48 | Upgrade |
Operating Expenses | 321.37 | 228.12 | 191.8 | 223.77 | 200.89 | 197.57 | Upgrade |
Operating Income | -121.09 | -40.66 | -13.95 | 6.33 | 42.17 | 27.24 | Upgrade |
Interest & Investment Income | - | - | - | - | - | 4.42 | Upgrade |
Other Non Operating Income (Expenses) | 10.75 | 10.75 | 11.49 | 2.01 | 1.85 | - | Upgrade |
EBT Excluding Unusual Items | -114.14 | -29.92 | -2.46 | 8.34 | 44.01 | 31.66 | Upgrade |
Gain (Loss) on Sale of Investments | 6.99 | 6.99 | 8.8 | 2.96 | -1.65 | - | Upgrade |
Pretax Income | -107.14 | -22.92 | 6.34 | 11.3 | 42.36 | 31.66 | Upgrade |
Income Tax Expense | -22.94 | -4.02 | 3.83 | 5.03 | 9.21 | 8.32 | Upgrade |
Net Income | -84.2 | -18.9 | 2.51 | 6.28 | 33.15 | 23.34 | Upgrade |
Net Income to Common | -84.2 | -18.9 | 2.51 | 6.28 | 33.15 | 23.34 | Upgrade |
Net Income Growth | - | - | -60.02% | -81.07% | 42.06% | -79.80% | Upgrade |
Shares Outstanding (Basic) | 59 | 58 | 57 | 56 | 56 | 54 | Upgrade |
Shares Outstanding (Diluted) | 59 | 58 | 58 | 57 | 57 | 55 | Upgrade |
Shares Change (YoY) | 1.34% | 1.03% | 1.01% | 0.11% | 3.14% | 0.63% | Upgrade |
EPS (Basic) | -1.43 | -0.33 | 0.04 | 0.11 | 0.60 | 0.43 | Upgrade |
EPS (Diluted) | -1.44 | -0.33 | 0.04 | 0.11 | 0.58 | 0.42 | Upgrade |
EPS Growth | - | - | -63.64% | -81.03% | 38.09% | -80.09% | Upgrade |
Free Cash Flow | -82.95 | -20.48 | -88.25 | 31.31 | 63.66 | 49.98 | Upgrade |
Free Cash Flow Per Share | -1.41 | -0.35 | -1.53 | 0.55 | 1.12 | 0.91 | Upgrade |
Gross Margin | 94.44% | 94.31% | 92.32% | 90.45% | 90.46% | 90.59% | Upgrade |
Operating Margin | -57.10% | -20.46% | -7.24% | 2.49% | 15.69% | 10.98% | Upgrade |
Profit Margin | -39.70% | -9.51% | 1.30% | 2.47% | 12.34% | 9.40% | Upgrade |
Free Cash Flow Margin | -39.12% | -10.30% | -45.81% | 12.31% | 23.69% | 20.14% | Upgrade |
EBITDA | -113.07 | -32.53 | -10.94 | 9.06 | 45.01 | 30.1 | Upgrade |
EBITDA Margin | -53.31% | -16.36% | -5.68% | 3.56% | 16.75% | 12.13% | Upgrade |
D&A For EBITDA | 8.03 | 8.13 | 3.01 | 2.73 | 2.84 | 2.86 | Upgrade |
EBIT | -121.09 | -40.66 | -13.95 | 6.33 | 42.17 | 27.24 | Upgrade |
EBIT Margin | -57.10% | -20.46% | -7.24% | 2.49% | 15.69% | 10.98% | Upgrade |
Effective Tax Rate | - | - | 60.42% | 44.47% | 21.75% | 26.28% | Upgrade |
Revenue as Reported | 212.07 | 198.77 | 192.64 | 254.38 | 268.68 | 248.17 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.